多西紫杉醇联合卡铂治疗乳腺癌肺转移患者的近期效果及对生存情况的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (454 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the Short term effect of Docetaxel combined with Carboplatin in the treatment of breast cancer patients with pulmonary metastasis and its impact on survival. Methods A total of 72 patients with lung metastasis of breast cancer admitted to the Sixth People′s Hospital of Huizhou City from January 2019 to January 2020 were selected as the research objects. They were divided into control group and research group by ball-touching method, with 36 patients in each group. The control group was treated with Carboplatin combined with Paclitaxel, and the study group was treated with Carboplatin combined with Docetaxel. The short-term efficacy, survival and adverse drug reactions of the two groups were compared. Results The objective effective rate of study group was higher than that in control group, and the difference was statistically significant (P<0.05). There was no significant difference in disease control rate between two groups (P>0.05). There was no significant difference in overall survival rate between the two groups (P>0.05). In terms of adverse reactions, there was no significant difference in the incidence of liver function damage, diarrhea, nausea and vomiting between the two groups (P>0.05). The incidence of hand-foot syndrome and leukopenia in the study group was lower than that in the control group, and the difference was statistically significant (P<0.05). Conclusion Combined treatment of Carboplatin and Docetaxel in patients with lung metastasis of breast cancer can improve the short-term objective response rate of patients, with higher safety and fewer side effects.

Key words： Docetaxel Carboplatin Breast cancer Lung metastasis Survival

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YE Zhenjun
	ZHOU Yuan

Cite this article:

YE Zhenjun,ZHOU Yuan. Short term effect of Docetaxel combined with Carboplatin in the treatment of breast cancer patients with pulmonary metastasis and its impact on survival[J]. 中国当代医药, 2022, 29(20): 95-97.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I20/95

[1]	Stefanou D，Kokkali S，Tripodaki ES，et al.Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer[J].Anticancer Res，2018，38（11）：6565-6569.
[2]	张树丹，李琪.替吉奥与卡培他滨治疗乳腺癌效果比较的Meta分析[J].中国当代医药，2021，28（15）：26-29.
[3]	杨传盛，王美姣，欧林洋，等.胸腔镜下内乳淋巴结切除术与开放性乳腺癌改良扩大根治术的对比研究[J].中国医药科学，2021，11（21）：216-219，224.
[4]	刘寿贵，林舜国.白蛋白结合型紫杉醇治疗紫杉类耐药转移性乳腺癌47例[J].肿瘤学杂志，2018，24（7）：692-695.
[5]	段彬，罗成静，罗海阳.Callispheres可载药栓塞微球联合多西紫杉醇TACE对原发性肝癌患者bFGF VEGF和MVD的影响[J].河北医学，2019，25（1）：14-18.
[6]	滕青华，王延虹，时磊，等.小剂量地塞米松预处理对乳腺癌患者多西紫杉醇化疗致过敏及其他不良反应的影响[J].癌症进展.2019，17（21）：74-77.
[7]	吴翔，岳春迪，崔小霞，等.多西紫杉醇与吡柔比星、环磷酰胺联合治疗进展期乳腺癌的效果评价[J].海南医学，2018，3（29）：120-122.
[8]	王薇，别克扎提·再孜提汉，周静，等.多西紫杉醇联合表阿霉素序贯化疗治疗三阴性乳腺癌的效果观察[J].山东医药，2018，58（4）：79-81.
[9]	Liu YC，Ma Y，An N，et al.Clinical efficacy of combination of pertuzumab，trastuzumab，and docetaxel for treatment of patients with HER2-positive breast cancer[J].Medicine，2019， 98（38）：e17262.
[10]	王道峰，伏俊，房三友.贝伐珠单抗联合DDP化疗方案治疗非小细胞肺癌患者的疗效观察[J].实用临床医药杂志，2020，24（22）：10-14.
[11]	张旭宇，李润浦，王艳丽，等.培美曲塞联合顺铂与标准TP方案用于肺腺癌患者术后化疗的近期疗效比较[J].实用癌症杂志，2019，34（5）：770-773.
[12]	国麟祺，陈颖，曲义坤，等.贝伐单抗治疗晚期胃癌的疗效及对肠黏膜屏障功能，基质金属蛋白酶2和9的影响[J].广西医学，2018，40（8）：894-897，916.
[13]	郭萍.曲妥珠单抗联合多西紫杉醇治疗复发转移乳腺癌的效果观察[J].中国实用医药，2020，15（4）：116-118.
[14]	李莎.表阿霉素联合多西紫杉醇序贯治疗三阴性乳腺癌的效果及预后观察[J].现代诊断与治疗，2019，30（19）：3345-3347.
[15]	梁有为，陆粤就，李业锦.多西紫杉醇联合卡培他滨治疗乳腺癌肝转移的临床观察[J].临床医学工程，2019，26（5）：631-632.